BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

EMA's CHMP reversed a prior decision and recommended approval of Avastin bevacizumab from Roche in combination with capecitabine for first-line metastatic breast cancer when other chemotherapy options, including taxanes or anthracyclines, are not considered appropriate. The drug is already approved in combination with paclitaxel. Upon reexamination of its initial opinion, CHMP concluded that the combination's...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >